Gwathmey KG, Ding H, Hehir M, Silvestri N (2024) How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis
Gut peptide alterations in type 2 diabetes and obesity: A narrative review
The guest joins around 8:26, but first Amanda tells about learning to curl (yes, as in, the icy Olympic sport!)
In future trials, cerebrospinal fluid levels of -synuclein oligomers and pro-inflammatory cytokines such as IL-6 and TNF- may serve as biomarkers of both neurodegeneration and treatment response in PD, potentially reflecting disease-modifying effects through reduced protein aggregation and neuroinflammation
Individual responses to semaglutide vary significantly based on genetics, metabolism, and previous weight loss attempts
This is your moment to feel better, look better, and save big